Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.

CONTEXT Preclinical studies demonstrate that nicotine administration leads to dopamine release in the ventral striatum. However, human studies reveal considerable interindividual variability in the extent of smoking-induced dopamine release. OBJECTIVE To determine whether common gene variants of the brain dopamine pathway explain this observed phenotypic variability in humans. DESIGN Blood samples were drawn to determine gene variants of dopamine system components, and positron emission tomography scanning with the radiotracer raclopride labeled with radioactive carbon (11C) was performed to measure smoking-induced dopamine release. SETTING Academic brain imaging center. PARTICIPANTS Forty-five tobacco-dependent smokers. INTERVENTIONS Subjects either smoked a cigarette (n = 35) or did not smoke (n = 10) during positron emission tomography scanning. MAIN OUTCOME MEASURES Gene variants of dopamine system components (the dopamine transporter variable nucleotide tandem repeat, D2 receptor Taq A1/A2, D4 receptor variable nucleotide tandem repeat, and catechol-O-methyltransferase Val158Met polymorphisms) and change in [11C]raclopride binding potential in the ventral caudate/nucleus accumbens on positron emission tomography scans. RESULTS For subjects who smoked during scanning, those with at least one 9 allele of the dopamine transporter variable nucleotide tandem repeat, fewer than 7 repeats of the D4 variable nucleotide tandem repeat, and the Val/Val catechol-O-methyltransferase genotype had greater decreases in binding potential (an indirect measure of dopamine release) with smoking than those with the alternate genotypes. An overall decrease in ventral caudate/nucleus accumbens binding potential in those who smoked compared with those who did not smoke was also found but was smaller in magnitude than previously reported. CONCLUSIONS Smokers with genes associated with low resting dopamine tone have greater smoking-induced (phasic) dopamine release than those with alternate genotypes. These findings suggest that dopamine system genotype variabilities explain a significant proportion of the interindividual variability in smoking-induced dopamine release and indicate that smoking-induced dopamine release has a genetic predisposition.

[1]  Shih-Jen Tsai,et al.  Association Study of Catechol- O-Methyltransferase Gene and Dopamine D4 Receptor Gene Polymorphisms and Personality Traits in Healthy Young Chinese Females , 2004, Neuropsychobiology.

[2]  G. Di Chiara,et al.  Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. , 1986, European journal of pharmacology.

[3]  W. Berrettini,et al.  The genetic determinants of smoking. , 2003, Chest.

[4]  A. Korten,et al.  Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. , 2000, American journal of medical genetics.

[5]  K. Schuh,et al.  Desire to smoke during spaced smoking intervals , 1995, Psychopharmacology.

[6]  D. Murphy,et al.  A genetic association for cigarette smoking behavior. , 1999, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[7]  E. Noble,et al.  Association of Seven Polymorphisms of the D2 Dopamine Receptor Gene with Brain Receptor-Binding Characteristics , 2004, Neurochemical Research.

[8]  L. Bierut,et al.  Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. , 2000, American journal of medical genetics.

[9]  Douglas W. Jones,et al.  Genotype Influences In Vivo Dopamine Transporter Availability in Human Striatum , 2000, Neuropsychopharmacology.

[10]  M. Jarvik,et al.  Nicotine Blood Levels and Subjective Craving for Cigarettes , 2000, Pharmacology Biochemistry and Behavior.

[11]  D. Comings,et al.  Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes--DRD2, D beta H, and DAT1. , 1996, American journal of medical genetics.

[12]  J O Rinne,et al.  The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers , 1998, Molecular Psychiatry.

[13]  K. Fagerström,et al.  Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. , 1978, Addictive behaviors.

[14]  I. T. Miller,et al.  High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. , 1997, American journal of medical genetics.

[15]  O. Pomerleau.  Individual differences in sensitivity to nicotine: Implications for genetic research on nicotine dependence , 1995, Behavior genetics.

[16]  X Li,et al.  Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. , 1992, Genomics.

[17]  H. V. Van Tol,et al.  Modulation of Intracellular Cyclic AMP Levels by Different Human Dopamine D4 Receptor Variants , 1995, Journal of neurochemistry.

[18]  M. Benwell,et al.  Regional variation in the effects of nicotine on catecholamine overflow in rat brain. , 1997, European journal of pharmacology.

[19]  W. Corrigall,et al.  The pedunculopontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: a correlative neuroanatomical and behavioral study , 2000, Neuroscience.

[20]  S. Fanti,et al.  Dopamine Transporter Gene Polymorphism, SPECT Imaging, and Levodopa Response in Patients with Parkinson Disease , 2004, Clinical neuropharmacology.

[21]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[23]  M. Munafo,et al.  The genetic basis for smoking behavior: a systematic review and meta-analysis. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[24]  G Blomqvist,et al.  Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  W C Eckelman,et al.  Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  J S Fowler,et al.  Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  A. Grace,et al.  The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes , 2004, Neuropsychopharmacology.

[28]  R. Shader.  Neurobiology of Drug Abuse. Monographs in Neural Sciences, Vol. 13 , 1988 .

[29]  S. David,et al.  Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[30]  G. Chiara,et al.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs , 1996, Nature.

[31]  T. Westfall,et al.  Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. , 1983, General pharmacology.

[32]  S. David,et al.  No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. , 2002, Pharmacogenetics.

[33]  B. Yamamoto,et al.  The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations. , 1998, The Journal of pharmacology and experimental therapeutics.

[34]  Marc Laruelle,et al.  Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[36]  D. Comings,et al.  The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. , 1996, Pharmacogenetics.

[37]  S. Cragg,et al.  Nicotine amplifies reward-related dopamine signals in striatum , 2004, Nature Neuroscience.

[38]  Hiroyuki Okada,et al.  Effect of Simple Motor Performance on Regional Dopamine Release in the Striatum in Parkinson Disease Patients and Healthy Subjects: A Positron Emission Tomography Study , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  J. Beuten,et al.  Progress in searching for susceptibility loci and genes for smoking‐related behaviour , 2004, Clinical genetics.

[40]  Richard E Carson,et al.  Nicotine-Induced Dopamine Release in Primates Measured with [11C]Raclopride PET , 2004, Neuropsychopharmacology.

[41]  R. Todd,et al.  Dopamine D2 and D3 receptors inhibit dopamine release. , 1994, The Journal of pharmacology and experimental therapeutics.

[42]  K. Franklin,et al.  The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine , 2005, Psychopharmacology.

[43]  C. Spielberger.  Manual for the State-Trait Anxiety Inventory (STAI) (Form Y , 1983 .

[44]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[45]  S. Otis,et al.  Acute Effects of Smoking on Human Cerebral Blood Flow: A Transcranial Doppler Ultrasonography Study , 2000, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[46]  A. Siderowf,et al.  Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT‐1 in striatum of asymptomatic volunteers and patients with Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[47]  J. Seibyl,et al.  Prediction of dopamine transporter binding availability by genotype: a preliminary report. , 2000, The American journal of psychiatry.

[48]  A. Lawrence,et al.  Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. , 2003, Brain : a journal of neurology.

[49]  I. Kopin,et al.  Monoamine oxidase and catecholamine metabolism. , 1994, Journal of neural transmission. Supplementum.

[50]  P. Greengard,et al.  Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons , 2004, Journal of neurochemistry.

[51]  A. Leshner,et al.  Drugs of abuse and the brain. , 1999, Proceedings of the Association of American Physicians.

[52]  K. Jhamandas,et al.  Regional release of [3H]dopamine from rat brain in vitro: effects of opioids on release induced by potassium, nicotine, and L-glutamic acid. , 1983, Canadian journal of physiology and pharmacology.

[53]  L. Kozlowski,et al.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. , 1991, British journal of addiction.

[54]  G. Swan,et al.  Non-replication of genetic association studies: is DAT all, folks? , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[55]  L. Epstein,et al.  Changes in food reward following smoking cessation: a pharmacogenetic investigation , 2004, Psychopharmacology.

[56]  W C Eckelman,et al.  Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  G. Koob.  Drugs of abuse: anatomy, pharmacology and function of reward pathways. , 1992, Trends in pharmacological sciences.

[58]  M. Piercey,et al.  Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release , 1998, Journal of Neural Transmission.

[59]  M. First,et al.  Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet , 1997 .

[60]  G. Uhl,et al.  The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. , 2003, European journal of pharmacology.

[61]  Osama Mawlawi,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[62]  C. Lerman,et al.  Interacting effects of genetic predisposition and depression on adolescent smoking progression. , 2004, The American journal of psychiatry.

[63]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[64]  Alain Dagher,et al.  The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride , 2004, Synapse.

[65]  Tianhua Niu,et al.  A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. , 2004, American journal of human genetics.

[66]  A. Lajtha,et al.  Differences in Nicotine-Induced Dopamine Release and Nicotine Pharmacokinetics Between Lewis and Fischer 344 Rats , 2001, Neurochemical Research.

[67]  E. Bowman,et al.  Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[68]  Jeffrey H. Meyer,et al.  Smoking-induced ventral striatum dopamine release. , 2004, The American journal of psychiatry.

[69]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[70]  E. Pothos,et al.  D2-Like Dopamine Autoreceptor Activation Reduces Quantal Size in PC12 Cells , 1998, The Journal of Neuroscience.

[71]  H. Fibiger,et al.  Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. , 1989, European journal of pharmacology.

[72]  E. Bowman,et al.  EVIDENCE SUGGESTING THE ROLE OF SPECIFIC GENETIC FACTORS IN CIGARETTE SMOKING , 1998 .

[73]  J. Hauser,et al.  Polymorphisms in the Dopamine, Serotonin, and Norepinephrine Transporter Genes and Their Relationship to Temperamental Dimensions Measured by the Temperament and Character Inventory in Healthy Volunteers , 2001, Neuropsychobiology.

[74]  P. Goldman-Rakic,et al.  Dopamine receptor-interacting proteins: the Ca(2+) connection in dopamine signaling. , 2003, Trends in pharmacological sciences.

[75]  M. Nöthen,et al.  Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers , 1999, Molecular Psychiatry.

[76]  T. Svensson,et al.  Systemic nicotine‐induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area , 1994, Synapse.

[77]  M Laruelle,et al.  D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene , 1998, Molecular Psychiatry.

[78]  W H Wilson,et al.  Substance abuse and cerebral blood flow. , 1991, The American journal of psychiatry.

[79]  G. Swan,et al.  Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR , 2005, The Pharmacogenomics Journal.

[80]  S. Ho,et al.  Human catechol-O-methyltransferase down-regulation by estradiol , 2003, Neuropharmacology.

[81]  K. Någren,et al.  The dopamine D2 receptor 5'-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo. , 1999, Pharmacogenetics.

[82]  E K Perry,et al.  D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. , 1997, Pharmacogenetics.

[83]  E P Noble,et al.  Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. , 1991, Archives of general psychiatry.

[84]  J. Littleton,et al.  Lack of Stereoselectivity in Ability of Nicotine to Release Dopamine from Rat Synaptosomal Preparations , 1983, Journal of neurochemistry.

[85]  R. Walton,et al.  Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. , 2004, Pharmacogenetics.

[86]  Marc Laruelle,et al.  The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans , 2001, Neuropsychopharmacology.

[87]  D. Wetter,et al.  The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[88]  J. Lowinson.  Substance Abuse: A Comprehensive Textbook , 1992 .

[89]  L. Carr,et al.  Stimulation of [3H]Dopamine Release by Nicotine in Rat Nucleus Accumbens , 1987, Journal of neurochemistry.

[90]  Y. Kohjimoto,et al.  Enhancement of [3H]dopamine release and its [3H]metabolites in rat striatum by nicotinic drugs , 1982, Brain Research.

[91]  C. Morris,et al.  Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. , 1998, Pharmacogenetics.

[92]  S. Janhunen,et al.  Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. , 2004, European journal of pharmacology.

[93]  B. Lanphear,et al.  Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors. , 2003, The Journal of pediatrics.

[94]  M. Schmidt,et al.  Marker gene polymorphisms in hyperkinetic disorder – predictors of clinical response to treatment with methylphenidate? , 2001, Neuroscience Letters.

[95]  H. V. Tol,et al.  The dopamine D4 receptors and mechanisms of antipsychotic atypicality , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[96]  J S Fowler,et al.  PET studies of the effects of aerobic exercise on human striatal dopamine release. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[97]  L. Kozlowski,et al.  Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[98]  T. Högberg,et al.  Synthesis of [methoxy-3H]- and [methoxy-11C]- labelled raclopride. Specific dopamine-D2 receptor ligands , 1987 .